Sodium-glucose cotransporter-2 (SGLT2) inhibitors, such as empagliflozin and canagliflozin, have been demonstrated to reduce the risk of CVD in T2D patients, especially those with existing cardiovascular risk factors. Here, SLC5A2 is linked to type 2 diabetes mellitus.